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Abstract 
Previously, we have described N-Bz-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-
nHex (IQM9.21, L-1) as an interesting multifunctional neuroprotective compound for 
the potential treatment of neurodegenerative diseases. Here, we describe new 
derivatives and different synthetic routes, such as chemoenzymatic and solid-phase 
synthesis, aiming to improve the previously described route in solution. The lipase-
catalysed amidation of L- and D-Glu diesters with N-benzyl-4-(2-aminoethyl)piperidine 
has been studied, using Candida antarctica and Mucor miehei lipases. In all cases, the 
α-amidated compound was obtained as the main product, pointing out that 
regioselectivity was independent of the reacting Glu enantiomer and the nature of the 
lipase. An efficient solid-phase route has been used to produce new donepezil-based L- 
and D-Glu derivatives, resulting in good yield. At micromolar concentrations, the new 
compounds inhibited human cholinesterases and protected neurons against toxic insults 
related to Alzheimer’s disease and cerebral ischemia. The CNS-permeable compounds 
N-Cbz-L-Glu(OEt)-[NH-2-(1-benzylpiperidin-4-yl)ethyl] (L-3) and L-1 blocked the 
voltage-dependent calcium channels and L-3 protected rat hippocampal slices against 
oxygen-glucose deprivation, becoming promising anti-Alzheimer and anti-stroke lead 
compounds. 
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Highlights 
 Enzymatic and solid-phase synthesis of new donepezil-based L- and D-Glu 
derivatives 
 Micro- and sub-micromolar inhibition of human cholinesterases 
 Neuroprotection in cellular models of Alzheimer’s disease and stroke 
 Blockade of voltage-dependent calcium channels in a human neuroblastoma cell 
line 
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Abbreviations: ACh, acetylcholine; AChE, acetylcholinesterase; AD, Alzheimer’s 
disease; Alloc, allyloxycarbonyl group; βA, beta-amyloid peptide; BuChE, 
butyrylcholinesterase; CAL-B, Candida antarctica lipase B; Cbz, benzyloxycarbonyl 
group; CNS, central nervous system; DMAP, 4-(dimethylamino)pyridine; EDC, 1-
ethyl-3-(3-dimethylaminopropyl)carbodiimide; Fmoc, fluorenylmethylenoxy group; 
HOBt, 1-hydroxybenzotriazole; HPLC-MS, high performance liquid chromatography 
joined to mass spectrometry; MML, Mucor miehei lipase; MTT, 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide; NBP-NH2, N-benzyl-4-(2-
aminoethyl)piperidine; NOX, NADPH oxidase; OGD/R, oxygen and glucose 
deprivation followed by re-oxygenation; ORAC, oxygen radical absorbance capacity; 
PAMPA-BBB, parallel artificial membrane permeation assay for the blood-brain 
barrier; PSL, Pseudomononas sp. lipase; R/O, rotenone plus oligomycin A; SH-SY5Y, 
human neuroblastoma cell line; TFA, trifluoroacetic acid; VDCC, voltage-dependent 
calcium channels. 
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1. Introduction 
As a consequence of the increasing life expectancy, Alzheimer's disease (AD) is 
currently a serious familiar, social, and economic problem [1]. AD is a complex 
neurodegenerative pathology occurring in the central nervous system (CNS), 
characterized by deposits of aberrant proteins namely β-amyloid (βA) and τ-protein, loss 
of synapses, and neuronal cell death, especially of cholinergic neurons. Nowadays, 
mitochondrial dysfunction and the subsequent oxidative stress are thought to be primary 
events in the complex and still non-completely known AD aetiology [2]. Over the last 
decades, several rational research strategies have been envisaged [3-5], but the current 
therapeutic options for the treatment of AD are limited to three acetylcholinesterase 
(AChE) inhibitors, namely donepezil, rivastigmine, and galantamine, and the N-methyl-
D-aspartate receptor antagonist memantine. Rivastigmine and galantamine are used for 
the treatment of mild-to-moderate AD, and memantine was approved for the 
management of moderate-to-severe AD [6,7]. Donepezil (Figure 1) is today the most 
used AChE inhibitor to treat mild, moderate, and severe AD [8]. 
Several studies have shown that in healthy brains AChE hydrolyses the majority of 
acetylcholine (ACh), while butyrylcholinesterase (BuChE) plays a secondary role. 
However, as AD progresses, cortical AChE activity decreases while that of BuChE 
significantly increases [9]. Therefore, both enzymes are involved in the regulation of 
ACh and are good therapeutic targets in the search for new drugs to increase cholinergic 
levels [10,11]. In this regard, recent clinical trials have demonstrated that patients 
treated with rivastigmine, a non-selective inhibitor of AChE and BuChE, showed minor 
cortical atrophic changes and attenuated loss of brain volumes [12,13].  
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Although many aspects of AD pathology remain unclear, increasing evidence 
supports a pivotal role for mitochondrial dysfunctions, such as oxidative stress or 
activation of unfolded protein response genes, in the pathogenesis and progression of 
AD [14,15]. Post-mortem studies showed significantly increased levels of peroxidation 
of lipids, proteins, and nucleic acids in vulnerable regions of the brain of patients with 
severe AD [16]. Moreover, enhanced oxidative damage in cellular structures was 
observed as an event preceding the appearance of other pathological hallmarks of AD, 
namely amyloid plaques and neurofibrillary tangles [17]. These observations suggest 
that drugs able to protect neurons from oxidative stress could be useful for either the 
prevention or the treatment of AD [18]. 
On the other hand, several age- and AD-related alterations in specific calcium-
regulating systems have been observed in brain cells, such as elevated intracellular 
calcium concentration, enhanced influx through voltage-dependent calcium channels 
(VDCC) and impaired ability of mitochondria to regulate homeostasis of this cation 
[19,20]. 
The complexity of AD and other neurodegenerative diseases has encouraged the 
active research for multifunctional molecules with two or more complementary 
biological activities, because they should be more effective than a ligand oriented to a 
single target [21-26]. Following this approach, in the last years we have reported several 
families of multifunctional compounds combining neurogenic, protective, antioxidant, 
cholinergic, and βA-reducing properties [27-34]. 
Among the above families, the donepezil-based hybrids carrying an L-glutamic acid 
(L-Glu) scaffold displayed interesting and complementary pharmacological properties. 
They efficiently inhibit human AChE and BuChE, protect neurons against damage 
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caused by mitochondrial free radicals, and are predicted to penetrate into the CNS by 
passive diffusion [34]. N-Bz-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-nHex (IQM-
9.21, L-1, Figure 1) was selected for further pharmacological assays, displaying VDCC 
blockade [35], infarct volume reduction in a photothrombotic stroke-model in mice [36] 
and neuroprotection against sodium and calcium overload in motor neuron-like NSC-34 
cells, as a model of amyotrophic lateral sclerosis [37].  
 
 
Figure 1. Structures of donepezil, IQM-9.21 (L-1), and new L- and D-Glu derivatives 
 
In our previous work, the synthesis of the L-Glu series was carried out following a 
classical 5-steps route in solution, involving protection-deprotection reactions. Although 
the products were obtained in acceptable overall yield (15-55%), some intermediates 
showed purification problems, requiring several chromatographic separations prior to 
their use [34]. With the aim of obtaining new L- and D-Glu N-benzylpiperidine 
derivatives related to L-1 and simplifying the previously described route in solution, in 
this work two different synthetic methodologies have been studied, namely enzymatic 
catalysis and solid-phase synthesis. The new derivatives have been evaluated as 
inhibitors of human cholinesterases, and as neuroprotective agents against 
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mitochondrial oxidative stress using two different models: the mixture of rotenone and 
oligomycin A, and the oxygen-glucose deprivation. We also studied the in vitro brain 
penetration of the new compounds and the effects of N-Cbz-L-Glu[NH-2-(1-
benzylpiperidin-4-yl)ethyl]-O-ethyl (L-3) in VDCC and in a tissue model of cerebral 
ischemia, compared to the reference compound L-1. 
 
2. Results and discussion 
2.1. Chemoenzymatic synthesis  
We explored the effectiveness of several hydrolases such as Candida antarctica 
lipase B (CAL-B), Pseudomononas sp. lipase (PSL), and Mucor miehei lipase (MML) 
in the amidation of L- and D-Glu diesters with N-benzyl-4-(2-aminoethyl)piperidine 
(NBP-NH2). Reactions were performed at analytical scale in anhydrous diisopropylether 
using NBP-NH2 (50 mM), Glu derivative (20 mM), enzyme (50 mg/mL), molecular 
sieves 4 Å (50 mg/mL), and acetanilide (3 mg/mL) as internal standard. Samples were 
stirred at 45 ºC and the reaction progression was monitored by HPLC-MS.  
Initially, we tested the amidation of N-Bz-D-Glu(OHex)-OHex with NBP-NH2 in the 
presence of CAL-B, PSL or MML. After 72 h, no reaction was detected with PSL or 
MML, and only in the case of CAL-B low conversion was observed by HPLC-MS, 
remaining more than 90% of the starting material. When the above reaction was 
repeated using double concentration of both CAL-B and molecular sieves (100 mg/mL) 
no significant improvement in conversion was observed. 
As the length of the n-hexyl chain could hinder the interaction of the D-Glu 
derivative with the active site of CAL-B, we envisaged the use of the diethylester of N-
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Bz-D-Glu (D-2) as substrate for the enzymatic reactions. The treatment of N-Bz-D-
Glu(OEt)-OEt with NBP-NH2 in the presence of CAL-B during 24 h displayed better 
conversion (~ 30%), which did not improve substantially after 72 h. For this reason, we 
decided to replace the benzoyl fragment by the benzyloxycarbonyl (Cbz) group, which 
could be better substrate for lipase reactions according to our previous results [38]. 
Reaction of N-Cbz-D-Glu(OEt)-OEt (D-2) with NBP-NH2 in the presence of CAL-B 
during 48 h yielded 88% of a monoamidated product, as detected by HPLC-MS. On the 
basis of this positive result, we performed a small-scale comparative study on D-2 and 
its enantiomer L-2 with CAL-B, MML and PSL (see Experimental Part for further 
details). By using PSL no reaction was detected, but in the case of CAL-B and MML 
we observed the formation of a monoamidated derivative as the main product of the 
enzymatic transformation. In the case of L-2 no starting material was observed, whereas 
about 10% of starting material remained unchanged for D-2. 
Then, the enzymatic reactions of L-2 and D-2 with CAL-B and MML were repeated, 
but in a preparative scale (without internal standard) to isolate and identify the products. 
Reactions using D-2 as starting material were accomplished during 92 h, while in the 
case of L-2 the enzymatic transformations were run for 24 h. Once the reactions were 
completed, enzyme and molecular sieves were removed by filtration and products were 
purified by column chromatography on silica gel, obtaining pure L-3 and D-3 
derivatives in 32-46% yield (Table 1). In all cases, the α-monoamidated derivative was 
obtained, as deduced from two-dimensional correlation experiments in NMR (see 
supplementary information for further details). 
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Table 1. Summary results of the lipase-catalysed preparative reactions 
 
Substrate Lipase Time (h) Product Yield (%)a 
L-2 CAL-B 24 L-3 46 
L-2 MML 24 L-3 41 
D-2 CAL-B 92 D-3 32 
D-2 MML 92 D-3 36 
 
a
Yield of isolated pure product 
 
The fact of obtaining the α-monoamide as the main product of the enzymatic 
reactions could be rationalized on the basis of our previous studies. In a previous paper 
about the amidation of D-Glu diesters with n-pentylamine, we described the lower 
reaction rate of these substrates and the minor regioselectivity compared to their L-
enantiomers, obtaining a mixture of α- and γ-pentylamides [38]. It may be expected that 
the bulkier nucleophile NBP-NH2 instead of n-pentylamine, reduced even more the 
reaction rate of the γ-ester and, consequently, α-monoamide was the main product 
formed. 
Comparing with the previously described 5-steps route in solution, enzymatic 
synthesis with CAL-B or MML provided similar overall yield (32-46%) and the 
advantage of involving only one synthetic step. Moreover, and as a result of the high 
enzyme regioselectivity, this methodology is suitable to obtain L- or D-Glu derivatives 
with a donepezil-derived fragment in the α-position, without the use of any protecting 
group.   
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2.2. Solid-phase synthesis 
To obtain the L- and D-Glu derivatives with an N-benzylpiperidine fragment in the γ-
position, a solid-phase synthesis was developed, using Wang resin (Scheme 1). The 
starting materials were N-Fmoc-L-Glu(OAll)-OH or N-Fmoc-D-Glu(OAll)-OH, which 
allow an orthogonal synthetic strategy. The fluorenylmethylenoxy group (Fmoc) can be 
easily removed under basic conditions, and the allyloxycarbonyl group (Alloc) can be 
deprotected under neutral conditions. 
Thus, Wang resin was coupled to N-Fmoc-L-Glu(OAll)-OH or N-Fmoc-D-Glu(OAll)-
OH, in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 4-
(dimethylamino)pyridine (DMAP), yielding intermediates N-Fmoc-L-Glu(OAll)-O-
resin (L-4) and N-Fmoc-D-Glu(OAll)-O-resin (D-4), respectively. Afterwards, the Alloc 
protecting group was removed using tetrakis(triphenylphosphine)palladium(0) 
[Pd(PPh3)4] in the presence of phenylsilane (PhSiH3) in dry dichloromethane under 
nitrogen atmosphere, and the resulting γ-free acids L-5 and D-5 were coupled with NBP-
NH2 in the presence of EDC, 1-hydroxybenzotriazole (HOBt), triethylamine, and 
DMAP. These reactions yielded intermediates N-Fmoc-L-Glu[NH-2-(1-benzylpiperidin-
4-yl)ethyl]-O-resin (L-6) and N-Fmoc-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-
resin (D-6), respectively. The next step was the Fmoc group cleavage with piperidine, 
providing intermediate resins L-7 and D-7. Their unprotected amino group was reacted 
with different aromatic carboxylic acids, using the previous conditions (EDC, HOBt, 
Et3N and DMAP) to give intermediates L-(8-10) and D-8. Finally, the cleavage of such 
resins with trifluoroacetic acid (TFA) afforded the carboxylic acids L-(11-13) and D-11, 
which were then purified by flash column chromatography and isolated in 23-76% 
overall yield (6 steps). The corresponding ethyl esters [L-(14-17) and D-14] or n-hexyl 
esters [D-1 and L-16] were obtained by reaction with EtOH or n-HexOH and thionyl 
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chloride (SOCl2) in moderate overall yield (18-46%, in 7 steps). Although this solid-
phase synthesis involved 2 more steps than the previously described route in solution 
and overall yield were similar, it presented as advantages that intermediates’ 
purification was not necessary and that desired final products were obtained rapidly in a 
high purity grade (above 80% by HPLC, after cleavage from the resin). 
 
 
Scheme 1. Solid-phase synthesis of L- and D-Glu derivatives with 
an N-benzylpiperidine in the γ-position.  
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2.3. Inhibition of human cholinesterases 
Firstly, compounds L-(2,3,11-17) and D-(1-3,11,14) were evaluated as inhibitors of 
human recombinant AChE (hAChE) and human plasmatic BuChE (hBuChE) using 
donepezil as reference and following the Ellman method [39]. Results are shown in 
table 2, in which we also included the previously described results of L-1 for 
comparative purposes [34]. In general, the new donepezil-based L- and D-Glu 
derivatives L-(3,11-17) and D-(1,3,11,14) were good inhibitors of both hChEs with IC50 
values in the low- and sub-micromolar range, whereas diethyl precursors L-2 and D-2 
did not inhibit any enzyme. 
From table 2 some structure – hChE’s inhibition relationships can be derived, 
regarding the position of the N-benzylpiperidine moiety at the amino acid framework 
(α- or γ-), the influence of the amino acid chirality (L- or D-), and the nature of the 
carboxyl group not attached to the N-benzylpiperidine fragment (free acids, ethyl- or 
hexyl esters). 
Compounds L- and D-3, containing an N-benzylpiperidine fragment in the α-carboxyl 
group, inhibited 10-fold better hBuChE than hAChE. However, the rest of L- or D-Glu 
derivatives 11-17, bearing the N-benzylpiperidine group in the γ-position, displayed a 
clear preference for hAChE. These differences may be due to the fact that the N-
benzylpiperidine moiety, responsible for hAChE-CAS binding, has more difficulties to 
reach the narrow catalytic gorge when is located in the α-position of the amino acid (L- 
and D-3) due to the higher steric hindrance of this part of the molecule. As the catalytic 
gorge of hBuChE is significantly bigger than that of hAChE [40], L- and D-3 possibly 
have less difficulty to interact with hBuChE. 
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Comparing pairs of enantiomers L- or D-(1,3,11,14), chirality seemed to have little 
influence on the hAChE inhibition, with the exception of L-11 that is about 2 orders of 
magnitude more active than D-11. Regarding hBuChE inhibition, D-Glu derivatives 
were better than their L-Glu counterparts, in some cases with a difference of one order 
of magnitude. Finally, ethyl- (14, 15, and 17) and hexyl ester derivatives (1 and 16) 
were better inhibitors of both hAChE and hBuChE than their corresponding free acid 
precursors (11-13). Moreover, all L-Glu or D-Glu acids 11-13 showed hBuChE IC50 
values above 10 µM, thus displaying a moderate selectivity towards hAChE, for which 
the IC50 values were between 0.76 and 20.0 µM.  
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Table 2. Inhibitory activities of new compounds in hAChE and hBuChE [IC50 (µM)]; neuroprotection (%) elicited by compounds at 0.3 M in 
the human neuroblastoma cell line SH-SY5Y, subjected to (i) the combination of rotenone (30 M) and oligomycin A (10 M) (R/O) or (ii) the 
oxygen-glucose deprivation followed by re-oxygenation (OGD/R); permeability values of compounds in the PAMPA-BBB assay (Pe, 10
-6
 cm s
-1
) 
with their predictive penetration in the CNS
a
. 
 IC50 (M)  Neuroprotection (%) vs.  PAMPA-BBB 
Compd. hAChE hBuChE  R/O OGD/R  Pe (10
-6
 cm s
-1
)
c
 Prediction 
L-1 0.53 ± 0.02 1.75 ± 0.6  44.1 ± 1.5*** 53.4 ± 1.7***  18.7 ± 1.6 cns+ 
D-1 0.89 ± 0.09 0.36 ± 0.04  13.0 ± 3.3** 32.2 ± 8.1**  13.9 ± 0.6 cns+ 
L-2 > 10 > 10  37.3 ± 5.6*** 51.6 ± 8.5***  n.d. n.d. 
D-2 > 10 > 10  34.7 ± 4.9*** 47.1 ± 9.8***  n.d. n.d. 
L-3 4.99 ± 0.16 0.40 ± 0.02  35.2 ± 4.7*** 42.7 ± 6.8***  21.0 ± 0.2 cns+ 
D-3 3.00 ± 0.09 0.17 ± 0.01  31.6 ± 4.4*** 47.0 ± 8.4***  16.7 ± 0.4 cns+ 
L-11 0.76 ± 0.11 > 10  46.5 ± 4.6*** 50.6 ± 7.4***  3.5 ± 0.1 cns+/- 
D-11 20.0 ± 0.8 82 ± 3  22.6 ± 2.1*** 38.5 ± 8.6*  4.6 ± 0.1 cns+/- 
L-12 6.4 ± 0.7 71 ± 2  34.6 ± 4.5*** 48.4 ± 9.5***  1.8 ± 0.1 cns- 
L-13 15.2 ± 0.5 97 ± 3  35.0 ± 2.3*** 45.0 ± 7.0***  2.3 ± 0.1 cns- 
L-14 0.85 ± 0.04 1.3 ± 0.2  38.6 ± 3.9*** 50.9 ± 9.3***  5.2 ± 0.1 cns+/- 
D-14 0.5 ± 0.2 0.39 ± 0.03  15.1 ± 2.7** 39.8 ± 6.9*  6.6 ± 0.2 cns+/- 
L-15 1.9 ± 0.5 0.30 ± 0.04  39.5 ± 4.7*** 42.4 ± 7.1***  4.5 ± 0.2 cns+/- 
L-16 3.04 ± 0.12 1.85 ± 0.07  22.1 ± 3.9** 31.8 ± 7.1**  9.6 ± 0.3 cns+ 
L-17 0.89 ± 0.08 3.8 ± 0.9  25.3 ± 4.4** 37.7± 6.7**  8.3 ± 0.2 cns+ 
Donepezil 0.010 ± 0.002 2.50 ± 0.07  n.d. n.d.  n.d.  
Melatonin n.d. n.d.  33.4 ± 4.0*** 31.4 ± 3.2**  n.d.  
a
Results are the
 
mean ± SEM of triplicates of at least four independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. n.d.: not determined. 
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2.4. Cell viability and neuroprotection studies in a human neuroblastoma cell line. 
Evaluation of antioxidant properties 
To explore the therapeutic potential of L- and D-Glu N-benzylpiperidine derivatives 
(1-3, 11-17), we studied cell viability and neuroprotective effects against oxidative 
stress in the human neuroblastoma cell line SH-SY5Y. Two toxic models were used: (i) 
the mixture of rotenone (30 µM) and oligomycin A (10 µM) (R/O) and (ii) oxygen and 
glucose deprivation (4 h) followed by re-oxygenation (20 h) (OGD/R).  
Rotenone and oligomycin A block mitochondrial electron transport chain complexes I 
and V, respectively [41,42]. A cocktail of these toxics generates high concentration of 
mitochondrial free radicals, decreases ATP synthesis and induces apoptosis, causing cell 
death. Thus, this mixture is described as a good experimental model of mitochondrial 
oxidative stress [27,31,43].  
Oxygen and glucose deprivation is an acute model of lesion produced by free radical 
generation during the re-oxygenation period [44]. This stimulus mimics what can occur 
in cerebral ischemia and AD, in which the hippocampus is profoundly affected and 
patients show symptoms of short-term memory loss [45].  
In both models, compounds were tested at 0.3 M and cell survival was quantified by 
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) colorimetric 
assay. MTT reduction in basal conditions was considered as 100% viability of cells 
without any treatment. Melatonin and L-1 were also tested for comparative purposes.  
First, possible cytotoxic effects of L- and D-Glu derivatives 1-3 and 11-17 were 
studied by exposing the cells to compounds at 0.3 M for 24 h. In all cases, cell survival 
was close to basal value, showing that the compounds had low toxicity (data not 
shown).  
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Compounds L-(1-3,11-17) and D-(1-3,11,14) displayed good levels of protection in 
both models (Table 2). Neuroprotection values ranged from 13% to 46% using R/O as 
toxic insult, and from 32% to 52% in the OGD/R protocol. In both models, L-Glu 
derivatives displayed better protection than their D-enantiomers, especially L-(1,11,14), 
in which the N-benzylpiperidine group was attached to the γ-position. We can highlight 
compound L-11 with the best neuroprotection values in both models. 
Then, we evaluated the radical scavenging properties of L- and D-Glu N-
benzylpiperidine derivatives (1,3,11-17) using the oxygen radical absorbance capacity 
(ORAC) assay and trolox as internal standard [27,28]. Tested compounds were inactive 
at 10 µM, with the exception of the series bearing an indole-3-carbonyl group in the 
side chain L-(12,15,16) that showed radical captures around 70-73% of the trolox value. 
As donepezil-based L- and D-Glu compounds showed little or null ability to capture 
oxygen radicals, their good neuroprotective properties towards oxidative stress as 
evidenced in the two cellular models used here could be mostly due to the activation of 
endogenous antioxidant pathways [46].  
 
2.5. In vitro blood-brain barrier permeation assay 
To explore whether L- and D-Glu derivatives would be able to penetrate into the 
brain, we used a parallel artificial membrane permeation assay for the blood-brain 
barrier (PAMPA-BBB) [47]. The in vitro permeabilities (Pe) of compounds L-(1,3,11-
17) and D-(1,3,11,14) through a lipid extract of porcine brain were determined (see 
Table 2 and Supporting Information).  
Predicted brain penetration appeared to be influenced mainly by the amino acid side 
chain and the nature of the carboxyl fragment (free acids, ethyl- or hexyl esters). 
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Regarding the side chain, the permeability order was found to be: carboxybenzyl > 
phenyl > 6-methoxy-2-naphthyl > indol-3-yl. In each of the above-mentioned families, 
hexyl esters were the most CNS-permeable compounds (L-1, D-1, L-16), all of them 
with positive prediction (cns+), followed by ethyl derivatives. Cbz ethyl esters (L-3 and 
D-3) and the 6-methoxy-2-naphthyl ethyl derivative L-17 could cross the BBB (cns+), 
whereas phenyl (L-14 and D-14) and indol-3-yl L-15 ethyl esters were predicted to have 
more difficulties to reach cerebral tissues (cns+/-). Finally, free acids were the worst 
CNS-permeable by passive diffusion, displaying negative (L-12 and L-13) or uncertain 
predictions (L-11 and D-11). 
Donepezil-based compounds L-1 and L-3, bearing the N-benzylpiperidine group in 
the γ- or in the α-position respectively, were chosen for additional pharmacological 
assays, on the basis of their balanced biological profile and their high predicted CNS-
permeability that could facilitate their further drug development.  
 
2.6. Study of the VDCC blocking effects in human neuroblastoma cells 
Emerging findings suggest that disruptions in calcium homeostasis are implicated in 
neuronal degeneration [48]. In previous work, we found that donepezil-based L-1 was a 
blocker of L-type VDCC that reduced K+-evoked [Ca2+]c transients with an IC50 value 
of 5.31 µM in bovine chromaffin cells. At 10 µM, L-1 decreased both the amplitude and 
the area of the Ca2+ transient evoked by high K+ by 40% and 80%, respectively [35]. 
Therefore, we thought of interest to study the potential VDCC blocking effect of L-Glu 
derivatives L-1 and L-3, but in the same cell model used to test their neuroprotective 
effect, the neuroblastoma SH-SY5Y line. For these experiments, cells were loaded with 
the Ca2+ sensitive fluorescent dye Fluo-4, thereafter, incubated for 15 min with 
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increasing concentrations of compounds. Then, cells were stimulated with a 
concentrated solution of KCl to obtain a final K+ concentration of 70 mM. Changes in 
fluorescence as a consequence of the increase in the [Ca2+]c elicited by high K
+ were 
measured in a fluorescence plate reader FluoStar Optima (BMG). A control with 
nifedipine (10 µM), an L-type VDCC blocker, was included in every individual 
experiment. Concentration-response curves of compounds L-1 and L-3 were elaborated 
with concentrations ranging from 0.3 to 100 µM (Figure 2). 
Donepezil-based compound L-1 blocked the increase in [Ca2+]c induced by high K
+ in 
a statistically significant manner at concentrations from 0.3 µM to 100 µM; blockade 
ranged from 21% to 62% (IC50 = 14.1 µM). Compound L-3 showed its maximum 
blockade (63%) at 100 µM, with an IC50 of 90.1 µM. By comparing their IC50 values, 
compound L-1 was over 6-fold better to block VDCCs than compound L-3. Looking 
into their structures, the change in the N-protecting group to Cbz moiety and the change 
in the position of the N-benzylpiperidine fragment from - to -position produced a 
significant reduction of its calcium channel blocker potency. 
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Figure 2. Inhibition by compounds L-1 and L-3 of the increment of [Ca2+]c evoked by 
K+ stimulation of neuronal SH-SY5Y cells. Panels A and B show the % of [Ca2+]c 
increase without any compound (basal) and in presence of increasing concentrations of 
L-1 and L-3 respectively. Nifedipine (10 µM) was used as positive control. Panel C 
shows concentration-response curves, measured as the maximum amplitude from 
baseline to the top of the plateau, fitted to non-linear curves for L-1 (square, continuous 
line) and L-3 (triangle, dotted line) and calculated IC50 values. 
 
 
2.7. Neuroprotection study in a tissue model of cerebral ischemia 
The potential neuroprotective effect of compound L-3 was also studied on an in vitro 
model of cerebral ischemia, the rat hippocampal slices subjected to a 15 min OGD 
period followed by a 2 h re-oxygenation period (OGD/R) [49,50] (see protocol on 
Figure 3). The functional impairment of mitochondria, promoted by the absence of the 
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oxygen supply, is increased when re-oxygenation triggers a massive production of 
reactive oxygen species raised by the OGD-induced overwork of the NADPH oxidase 
(NOX) enzyme. Cell viability, normalized to 100% of control slices, was reduced by 
40% after OGD/R (black column in Figure 3). This damage was mitigated by 55% in 
the presence of 3 M of compound L-1 [36]. Compound L-3 showed a concentration-
dependent effect with 48 ± 2 % protection at the concentration of 1 M and maximal 
protection of 69 ± 2 % at the concentration of 3 M, being more efficient than the 
reference compound L-1 at the same concentration. 
 
Figure 3. Compound L-3 increases cell viability of rat hippocampal slices subjected 
to OGD/R. The experimental protocol is illustrated on the top part of the figure. The 
graph corresponds to the mean ± SEM of 4 independent experiments in triplicate. 
###
p<0.001 respect control slices (not exposed to OGD/R) and *p<0.05, **p<0.01, 
***p<0.001 respect to slices subjected to OGD/R. Data of compound L-1 are taken 
from Ref. [36] 
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3. Conclusions 
In summary, we have developed two synthetic routes to obtain multifunctional L- and 
D-Glu derivatives, which simplify the previously described synthesis in solution [34]. 
The chemoenzymatic synthesis allowed the regioselective introduction of an N-
benzylpiperidine moiety in the α-carbonyl group of Glu diethyl ester derivatives. 
Regioselectivity was independent of the reacting Glu enantiomer and of the nature of 
the lipase assayed. In all cases, enzymatic reactions were clean, which facilitates the 
isolation and purification of products. Best conversions were obtained in the L-series 
and using CAL-B. The solid-phase synthesis enabled the preparation of L- and D-Glu 
derivatives bearing the N-benzylpiperidine fragment in the γ-position. The final 
products were obtained in high overall yield. 
The synthesised compounds showed a multifunctional profile with good inhibition of 
human ChEs in the micro- and sub-micromolar range and neuroprotective properties 
against the oxidative stress originated by the mixture of rotenone and oligomycin A or 
by the oxygen and glucose deprivation. In the human neuroblastoma cell line SH-
SY5Y, compounds L-1 and L-3 blocked the increase in [Ca
2+
]c induced by high K
+
, with 
IC50 values in the micromolar range. Finally, in an in vitro model of cerebral ischemia 
using the rat hippocampal slices subjected to an OGD/R protocol, compound L-3 at 3 
M showed an interesting protection of 69%. Their multitarget profile is complemented 
by the positive data to be able to penetrate into the CNS by passive diffusion. Thus, we 
can conclude that these donepezil-based Glu derivatives show a balanced 
multifunctional profile of interest in the search for new drugs for the treatment of AD 
and cerebral ischemia.  
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4. Experimental section 
4.1. Chemistry. General methods 
Reagents were purchased from common commercial suppliers (Sigma-Aldrich, 
Acros, Bachem, Merck, ABCR or TCI) and were used without further purification. 
Thin-layer chromatography (TLC) was performed on silica-gel-coated aluminium foils 
(silica gel 60/kieselguhr F254, Merck) and compounds were detected with UV light (λ = 
254 nm) or with ninhydrin. Chromatographic separations were performed either using 
an Isolera One (Biotage) purification system, or using flash-column chromatography on 
silica gel (Biotage SNAP FSK0-1107 cartridges and Kiesegel 60 Merck of 230-400 
mesh, respectively). Melting points were determined in a Mettler Toledo MP70 
apparatus. Optical rotations were determined with a Perkin-Elmer 241 MC polarimeter 
at room temperature (ca. 293 K). Nuclear magnetic resonance spectra were recorded 
using a Varian 500, Varian Inova-400 and Varian Mercury-400. Chemical shifts are 
expressed in parts per million (δ, ppm) using the residual solvent proton as internal 
standard and J values are reported in hertz. Spin multiplicities are expressed as s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br (broad). IR spectra 
were recorded with a Perkin Elmer Spectrum One FT-IR spectrometer. The electrospray 
ionization-high resolution mass spectra (ESI-HRMS) were performed by using a liquid 
chromatography apparatus HP-1200 (Agilent Technologies) with a Q-TOF 6520 hybrid 
mass spectrometer. HPLC-MS analyses were performed on Alliance Waters 2695 
equipment, with a UV detector photodiode array Waters 2996 with MS detector 
Micromass ZQ (Waters), using a SunFire C18, 3.5 μm, 4.6 mm x 50 mm column, and a 
gradient of CH3CN/H2O/HCOOH (2% aq sol) from 15:80:5 to 95:0:5 v/v/v for 5 
minutes at 1.0 mL/min, if not otherwise indicated. HPLC analyses were used to confirm 
the purity of all compounds (≥ 95%).  
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4.2. General procedure for the lipase-catalysed reactions 
From commercially available N-Cbz-L-Glu and D-Glu and following described 
methods [38,51], intermediates N-Cbz-L-Glu(OEt)-OEt (L-2) and N-Cbz-D-Glu(OEt)-
OEt (D-2) were obtained in 79% and 13% yield, respectively. To a solution of L-2 or D-
2 (20 mM) and NBP-NH2 (50 mM) in dry diisopropylether (iPr2O), CAL-B (Candida 
antarctica lipase B) or MML (Mucor miehei lipase) (50 mg/mL) and molecular sieves 4 
Å (50 mg/mL) were added. The reaction mixture was agitated in an orbital shaker at 45 
ºC. The reaction was followed by HPLC-MS. When the reaction was completed, the 
enzyme and molecular sieves were filtered off and washed with CH2Cl2. The solvent 
was evaporated under reduced pressure and the crude was purified by flash column 
chromatography using CH2Cl2/MeOH 9:1 as eluent. 
 
4.2.1. N-Carboxybenzyl-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl (L-3) 
Following the general procedure, from L-2 (0.60 g, 1.78 mmol), NBP-NH2 (0.98 mL, 
4.45 mmol), 4.5 g of molecular sieves and 4.5 g of enzyme in 90 mL of dry iPr2O, 
compound L-3 was obtained in 22 hours as a white solid of mp 105-106 ºC (bibl. 107-
108 ºC [52]) and [α]D
20
: -3.5 (c = 1, CHCl3). Yield of L-3 using CAL-B as enzyme: 0.42 
g (0.83 mmol, 46%), yield of L-3 using MML: 0.37 g (0.73 mmol, 41%). 
1
H NMR (500 
MHz, CDCl3): δ 7.31 (m, 10H, 2Ph), 6.27 (m, 1H, NHCOCα), 5.67 (br d, 1H, NHCα), 
5.08 (s, 2H, H1’), 4.17 (m, 1H, Hα), 4.12 (q, J = 7.2 Hz, 2H, H1’’), 3.54 (s, 2H, H8), 
3.26 (m, 2H, H1), 2.91 (br d, J = 11.5 Hz, 2H, H5eq,6eq), 2.49 (dt, J = 17.0, 7.0 Hz, 1H, 
Hγ1), 2.36 (dt, J = 17.0, 7.0 Hz, 1H, Hγ2), 2.11 (m, 1H, Hβ1), 1.99 (m, 2H, H5ax,6ax), 
1.93 (m, 1H, Hβ2), 1.66 (br d, J = 10.8 Hz, 2H, H4eq,7eq), 1.43 (m, 2H, H2), 1.35 (m, 
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2H, H4ax,7ax), 1.31 (m, 1H, H3), 1.24 (t, J = 7.2 Hz, 3H, H2’’). 13C NMR (125 MHz, 
CDCl3): δ 173.7 (COCγ), 171.1 (COCα), 156.4 (CONHCα), 137.6, 136.3, 129.6 (2C), 
128.7 (2C), 128.4, 128.3 (2C), 128.1 (2C) and 127.4 (2 Ph); 67.2 (C1’), 63.3 (C8), 61.0 
(C1’’), 54.4 (Cα), 53.6 (C5,6), 37.4 (C1), 36.1 (C2), 33.4 (C3), 31.8 (C4,7), 30.6 (Cγ), 
28.3 (Cβ), 14.3 (C2’’). IR (neat) ῡ 3436, 3305, 3066, 3033, 2928, 2799, 1726, 1690, 
1650, 1540, 1447, 1379, 1280, 1243, 1196, 1017, 740, 699 cm
-1
. HRMS (ESI
+
): m/z 
calcd for C29H40N3O5 [M+H]
+
 510.2962, found 510.2967. HPLC-MS: tR = 2.92 min 
(96%). 
 
4.2.2. N-Carboxybenzyl-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl (D-3) 
Following the general procedure, from D-2 (0.30 g, 0.88 mmol), NBP-NH2 (0.49 mL, 
2.20 mmol), 2.2 g of molecular sieves and 2.2 g of enzyme in 44 mL of dry iPr2O, 
compound D-3 was obtained in 92 hours as a white solid of mp 100-102 ºC and [α]D
20
: 
+2.8 (c = 1, CHCl3). Yield using CAL-B as enzyme: 0.14 g (0.28 mmol, 32%), yield 
with MML: 0.17 g (0.32 mmol, 36%). 
1
H NMR (500 MHz, CDCl3): δ 7.31 (m, 10H, 
2Ph), 6.24 (m, 1H, NHCOCα), 5.66 (br d, 1H, NHCα), 5.09 (s, 2H, H1’), 4.17 (m, 1H, 
Hα), 4.12 (q, J = 7.2 Hz, 2H, H1’’), 3.49 (s, 2H, H8), 3.26 (m, 2H, H1), 2.87 (bd, J = 
11.0 Hz, 2H, H5eq, 6eq), 2.49 (dt, J = 17.0, 7.0 Hz, 1H, Hγ1), 2.36 (dt, J = 17.0, 7.0 Hz, 
1H, Hγ2), 2.10 (m, 1H, Hβ1), 1.93 (m, 3H, Hβ2,5ax, 6ax), 1.64 (br d, J = 8.9 Hz, 2H, 
H4eq, 7eq), 1.43 (m, 2H, H2), 1.28 (m, 3H, H3, 4ax, 7ax), 1.24 (t, J = 7.2 Hz, 3H, 
H2’’). 13C NMR (125 MHz, CDCl3): δ 173.7 (COCγ), 171.0 (COCα), 156.4 
(CONHCα), 138.2, 136.3, 129.4 (2C), 128.7 (2C), 128.4, 128.3 (2C), 128.2 (2C) and 
127.2 (2Ph); 67.2 (C1’), 63.5 (C8), 61.0 (C1’’), 54.4 (Cα), 53.8 (C5,6), 37.4 (C1), 36.2 
(C2), 33.6 (C3), 32.1 (C4,7), 30.6 (Cγ), 28.3 (Cβ), 14.3 (C2’’). IR (KBr) ῡ 3436, 3305, 
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3066, 2926, 2798, 1726, 1690, 1649, 1542, 1447, 1379, 1280, 1243, 1197, 1175, 1077, 
1017, 740, 699 cm
-1
. HRMS (ESI
+
): m/z calcd for C29H40N3O5 [M+H]
+
 510.2962, found 
510.2966. HPLC-MS: tR = 2.80 min (97%). 
 
4.3. General procedure for the solid-phase synthesis of amino acid derivatives 
All solid-phase reactions were performed in an orbital shaker at room temperature. 
Wang resin was suspended in DMF, shaken for 5 min, and the solvent was filtered off. 
This process was repeated twice for resin swelling. After every step, the following 
general washing procedure was carried out: twice with (MeOH, THF, pentane, CH2Cl2), 
once with (MeOH, DMF, pentane, THF), and twice with (pentane, CH2Cl2, pentane), 
using 10-15 mL of each solvent and shaking for 2 min. After every step, we considered 
to get a quantitative yield to calculate the amount of reagents for the next reaction. 
4.3.1. Anchor of N-Fmoc-L-Glu(OAll)-OH or N-Fmoc-D-Glu(OAll)-OH to Wang resin 
To a solution of N-Fmoc-L-Glu(OAll)-OH or N-Fmoc-D-Glu(OAll)-OH (491 mg, 
1.2 mmol) in 20 mL of CH2Cl2:DMF (9:1, v/v), 1-ethyl-3-(-3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC HCl, 230 mg, 1.2 mmol) was added, and the mixture 
was stirred for 10 min. Then, this solution was added to a suspension of the swollen 
Wang resin (909 mg, 1.1 mmol/g, 1.0 mmol) in DMF (20 mL) and the mixture was 
stirred for an additional 5 min period. Afterward, 4-dimethylaminopyridine (DMAP, 12 
mg, 0.1 mmol) was added and the mixture was shaken for 16 h. Then, the solvent was 
filtered off and the corresponding resin, L-4 or D-4, was washed following the general 
procedure and then dried under vacuum. 
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4.3.1.1. N-Fmoc-L-Glu(OAll)-O-resin (L-4). IR (KBr) ῡ 3421, 3059, 3025, 2921, 2840, 
1732, 1612, 1512, 1493, 1451, 1380, 1299, 1220, 1172, 1030, 822, 758, 740, 698, 539 
cm
-1
. 
4.3.1.2. N-Fmoc-D-Glu(OAll)-O-resin (D-4). IR (KBr) ῡ 3420, 3060, 3025, 2920, 2840, 
1735, 1615, 1514, 1496, 1453, 1382, 1298, 1224, 1174, 1033, 824, 760, 742, 670, 540 
cm
-1
.  
 
4.3.2. Alloc deprotection 
Under nitrogen atmosphere, to a suspension of resin L-4 or D-4 (1 mmol) in dry 
CH2Cl2 a solution of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, 116 mg, 0.1 
mmol) and phenylsilane (PhSiH3, 541 mg, 5 mmol) was added, and the reaction mixture 
was shaken for 45 min. Then, solvent was filtered off and the resin was washed 3 times 
with CH2Cl2. The above process was repeated a second time, using the same quantity of 
every reagent for other 45 min. Then, the solvent was filtered off and the resulting resin, 
L-5 or D-5, was washed following the general procedure and dried under vacuum.  
4.3.2.1. N-Fmoc-L-Glu(OH)-O-resin (L-5). IR (KBr) ῡ 3430, 3055, 3025, 2920, 2846, 
1725, 1647, 1613, 1512, 1493, 1451, 1381, 1220, 1172, 1029, 822, 758, 741, 698, 538 
cm
-1
. 
4.3.2.2. N-Fmoc-D-Glu(OH)-O-resin (D-5). IR (KBr) ῡ 3432, 3058, 3026, 2920, 2848, 
1726, 1650, 1615, 1513, 1497, 1452, 1384, 1223, 1172, 1030, 823, 760, 742, 699, 537 
cm
-1
. 
  
 28 
 
4.3.3. Amine coupling 
Resin L-5 or D-5 (1 mmol) was suspended in 20 mL of DMF/CH2Cl2 (2:1, v/v) and 
then, EDC HCl (383 mg, 2 mmol), 1-hydroxybenzotriazole (HOBt H2O, 306 mg, 2 
mmol), NBP-NH2 (437 mg, 2 mmol), triethylamine (348 µL, 2.5 mmol) and DMAP (12 
mg, 0.1 mmol) were successively added. The reaction mixture was shaken for 16 h and 
then the solvent was filtered off. Resin L- or D-6 was washed following the general 
procedure and dried under vacuum. 
4.3.3.1. N-Fmoc-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (L-6). IR (KBr) ῡ 
3422, 3059, 3025, 2919, 2841, 1734, 1646, 1613, 1512, 1493, 1451, 1368, 1301, 1220, 
1170, 1016, 821, 758, 740, 697, 539 cm
-1
. 
4.3.3.2. N-Fmoc-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (D-6). IR (KBr) ῡ 
3424, 3060, 3025, 2920, 2840, 1736, 1650, 1615, 1513, 1494, 1450, 1370, 1300, 1220, 
1170, 1018, 820, 760, 745, 695, 540 cm
-1
. 
 
4.3.4. Fmoc deprotection 
Resin L-6 or D-6 (1 mmol) was suspended in DMF (16 mL) and a piperidine solution 
20 % in DMF (4 mL) was added. The mixture was shaken for 20 min, the solvent was 
filtered off, and the resin was washed twice with DMF. The same process was 
performed a second time with the same amount of piperidine for other 20 min. Then, the 
solvent was filtered off and the corresponding resin L-7 or D-7 was washed following 
the general procedure and dried under vacuum.  
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4.3.4.1. L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (L-7). IR (KBr) ῡ 3421, 
3059, 3025, 2920, 2850, 1735, 1648, 1612, 1512, 1493, 1452, 1369, 1301, 1223, 1171, 
1016, 822, 758, 698, 540 cm
-1
. 
4.3.4.2. D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (D-7). IR (KBr) ῡ 3420, 
3060, 3030, 2924, 2855, 1740, 1650, 1615, 1515, 1496, 1458, 1370, 1300, 1225, 1174, 
1016, 822, 760, 700, 542 cm
-1
. 
 
4.3.5. Introduction of the aromatic substituents – acid coupling 
To a solution of the corresponding carboxylic acid (1.2 mmol) in 20 mL of 
CH2Cl2:DMF (1:1, v/v), EDC HCl (230 mg, 1.2 mmol) and HOBt (1.2 mmol) were 
added and stirred for 10 min. This solution was added to a suspension of resin L-7 or D-
7 (1 mmol) in 20 mL of DMF/CH2Cl2 (1:1, v/v) and then, Et3N (223 µL, 1.6 mmol) and 
DMAP (12 mg, 0.1 mmol) were added and the mixture was stirred for 16 h. Then the 
solvent was filtered off and resins L-(8-10) and D-8 were washed following the general 
procedure and then dried under vacuum. 
4.3.5.1. N-Benzoyl-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (L-8). IR (KBr) 
ῡ 3422, 3059, 3025, 2919, 2846, 1736, 1643, 1610, 1512, 1492, 1451, 1375, 1220, 
1170, 1109, 1027, 820, 757, 697, 536 cm
-1
. 
4.3.5.2. N-Benzoyl-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (D-8). IR (KBr) 
ῡ 3422, 3059, 3025, 2921, 2850, 1740, 1653, 1613, 1513, 1493, 1452, 1376, 1221, 
1172, 1110, 1027, 823, 758, 698, 539 cm
-1
. 
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4.3.5.3. N-(Indole-3-carbonyl)-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin (L-
9). IR (KBr) ῡ 3421, 3059, 3025, 2919, 2846, 1738, 1636, 1512, 1493, 1452, 1371, 
1300, 1171, 1016, 821, 747, 698, 538 cm
-1
. 
4.3.5.4. N-(6-Methoxy-2-naphthoyl)-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-resin 
(L-10). IR (KBr) ῡ 3429, 3055, 3025, 2921, 2856, 1736, 1629, 1511, 1452, 1370, 1214, 
1169, 1121, 1028, 820, 757, 698, 538 cm
-1
. 
 
4.3.6. Resin cleavage – Synthesis of N-(arylcarbonyl)-L-(or D-)-Glu[NH-2-(1-
benzylpiperidin-4-yl)ethyl]-OH 
Trifluoroacetic acid (TFA, 2 mL) was added to a suspension of each resin L-(8-10) or 
D-8 in dry CH2Cl2 (8 mL) and the mixture was stirred for 20 min. Resin was filtered off 
and washed with CH2Cl2 (3 x 20 mL). The organic phases were combined and 
evaporated under reduced pressure, using sequential additions of EtOAc (3 x 20 mL) 
and Et2O (3 x 20 mL) to remove the excess of TFA. 
 
4.3.6.1. N-Benzoyl-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-OH (L-11) 
Following the general procedure, from 2.1 g of Wang resin, compound L-11 was 
obtained as a white solid (0.80 g, 1.76 mmol, 76% over six steps) of mp 70-72 ºC and 
[α]D
20
: -8.4 (c = 1, CH3OH). 
1
H NMR (400 MHz, CD3OD): δ 7.89 (m, 2H, H Ar), 7.56 
(m, 1H, H Ar), 7.48 (m, 7H, H Ar), 4.57 (m, 1H, Hα), 4.26 (s, 2H, H8), 3.42 (m, 2H, 
H5eq, 6eq), 3.20 (m, 2H, H1), 2.97 (m, 2H, H5ax, 6ax), 2.39 (m, 2H, Hγ), 2.32 (m, 1H, 
Hβ1), 2.11 (m, 1H, Hβ2), 1.95 (m, 2H, H4eq, 7eq), 1.60 (m, 1H, H3), 1.43 (m, 2H, H2), 
1.37 (m, 2H, H4ax, 7ax). 
13
C NMR (100 MHz, CD3OD): δ 175.0 (COCα), 174.8 
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(COCγ), 170.3 (CONHCα), 135.2 (C Ar), 133.0 (C Ar), 132.3 (2C Ar), 131.2 (2C Ar), 
130.4 (C Ar), 130.3 (2C Ar), 129.6 (2C Ar), 128.5 (C Ar), 61.8 (C8), 53.8 (Cα), 53.7 
(C5,6), 37.2 (C1), 36.2 (C2), 33.3 (Cγ), 32.0 (C3), 30.3 (C4,7), 28.0 (Cβ). IR (KBr) ῡ 
3401, 3060, 2931, 1661, 1537, 1454, 1201, 1134, 720, 702 cm
-1
. HRMS (ESI
+
): m/z 
calcd for C26H34N3O4 [M+H]
+
 452.2544, found 452.2556. HPLC-MS: tR = 2.06 min 
(98%).  
 
4.3.6.2. N-Benzoyl-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-OH (D-11) 
Following the general procedure, from 1.8 g of Wang resin, a residue was obtained 
and purified by flash column chromatography using CH2Cl2/MeOH (increasing polarity 
from 9:1 to 4:1). Compound D-11 was obtained as a white solid (0.21 g, 0.47 mmol, 
23% over six steps) of mp 75-77 ºC and [α]D
20
: +7.6 (c = 1, CH3OH). 
1
H NMR (400 
MHz, CD3OD): δ 7.85 (m, 2H, H Ar), 7.48 (m, 3H, H Ar), 7.36 (m, 5H, H Ar), 4.45 (m, 
1H, Hα), 3.88 (s, 2H, H8), 3.14 (m, 4H, H1, 5eq, 6eq), 2.49 (m, 2H, H5ax, 6ax), 2.30 
(m, 2H, Hγ), 2.21 (m, 1H, Hβ1), 2.06 (m, 1H, Hβ2), 1.78 (m, 2H, 4eq, 7eq), 1.38 (m, 5H, 
H2, 3, 4ax, 7ax). 
13
C NMR (100 MHz, CD3OD): δ 178.2 (COCα), 175.6 (COCγ), 169.2 
(CONHCα), 135.7 (C Ar), 134.1 (C Ar), 132.7 (2C Ar), 131.7 (2C Ar), 129.9 (C Ar), 
129.8 (2C Ar), 129.6 (2C Ar), 128.3 (C Ar), 62.7 (C8), 56.4 (Cα), 53.9 (C5,6), 37.6 
(C1), 36.3 (C2), 33.9 (Cγ), 33.1 (C3), 31.2 (C4,7), 30.3 (Cβ). IR (KBr) ῡ 3401, 3063, 
2929, 1643, 1602, 1578, 1544, 1482, 1397, 743, 699 cm
-1
. HRMS (ESI
+
): m/z calcd for 
C26H34N3O4 [M+H]
+
 452.2544, found 452.2527. HPLC-MS: tR = 2.08 min (98%).  
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4.3.6.3. N-[Indole-3-carbonyl]-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-OH (L-12) 
Following the general procedure, starting with 1.4 g of Wang resin, a residue was 
obtained and purified by flash column chromatography using CH2Cl2/MeOH 
(increasing polarity from 9:1 to 4:1). Compound L-12 was obtained as a yellow solid 
(0.27 g, 0.54 mmol, 36% over six steps) of mp 87-89 ºC and [α]D
20
: -4.2 (c = 1, 
CH3OH). 
1
H NMR (400 MHz, CD3OD): δ 8.10 (m, 1H, H Ar), 7.99 (s, 1H, H Ar), 7.41 
(m, 6H, H Ar), 7.15 (m, 2H, H Ar), 4.57 (m, 1H, Hα), 4.10 (s, 2H, H8), 3.12 (m, 4H, 
H1, 5eq, 6eq), 2.81 (m, 2H, H5ax, 6ax), 2.38 (m, 2H, Hγ), 2.29 (m, 1H, Hβ1), 2.10 (m, 
1H, Hβ2), 1.81 (m, 2H, H4eq, 7eq), 1.52 (m, 1H, H3), 1.32 (m, 4H, H2, 4ax, 7ax). 
13
C 
NMR (100 MHz, CD3OD): δ 176.4 (COCα), 175.1 (COCγ), 168.1 (CONHCα), 138.1 
(2C Ar), 132.3 (C Ar), 131.1 (C Ar), 130.5 (C Ar), 130.3 (2C Ar), 129.7 (C Ar), 127.0 
(C Ar), 123.6 (C Ar), 122.2 (C Ar), 121.7 (C Ar), 113.0 (C Ar), 111.6 (C Ar), 61.6 (C8), 
53.8 (Cα), 53.5 (C5,6), 37.2 (C1), 35.9 (C2), 33.5 (Cγ), 31.8 (C3), 30.1 (C4,7), 28.8 
(Cβ). IR (KBr) ῡ 3414, 3068, 2931, 1677, 1640, 1537, 1437, 1204, 1134, 751, 722 cm-1. 
HRMS (ESI
+
): m/z calcd for C28H35N4O4 [M+H]
+
 491.2653, found 491.2675. HPLC-
MS: tR = 2.47 min (96%).  
 
4.3.6.4. N-[6-Methoxy-2-naphthoyl]-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-OH (L-
13) 
Following the general procedure, starting with 1.4 g of Wang resin, a residue was 
obtained and purified by flash column chromatography using CH2Cl2/MeOH 
(increasing polarity from 9:1 to 8:2) Compound L-13 was obtained as a white solid 
(0.20 g, 0.38 mmol, 25% over six steps) of mp 75-78 ºC and [α]D
20
: -3.7 (c = 1, 
CH3OH). 
1
H NMR (400 MHz, CD3OD): δ 8.38 (m, 1H, H Ar), 7.88 (m, 3H, H Ar), 7.45 
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(m, 5H, H Ar), 7.30 (m, 1H, H Ar), 7.21 (m, 1H, H Ar), 4.60 (m, 1H, Hα), 4.20 (s, 2H, 
H8), 3.93 (s, 3H, H11’’), 3.20 (m, 4H, H1, 5eq, 6eq), 2.89 (m, 2H, H5ax, 6ax), 2.42 (m, 
2H, Hγ), 2.34 (m, 1H, Hβ1), 2.16 (m, 1H, Hβ2), 1.88 (m, 2H, 4eq, 7eq), 1.57 (m, 1H, 
H3), 1.35 (m, 4H, H2, 4ax, 7ax). 
13
C NMR (100 MHz, CD3OD): δ 186.5 (COCα), 175.0 
(COCγ), 170.2 (CONHCα), 160.9 (C6’), 138.1 (2C Ar), 132.2 (C Ar), 131.6 (C Ar), 
131.2 (C Ar), 130.3 (3C Ar), 130.1 (C Ar), 129.3 (C Ar), 128.9 (C Ar), 128.2 (C Ar), 
125.6 (C Ar), 120.9 (C Ar), 106.7 (C Ar), 61.6 (C8), 55.9 (C11’’), 54.3 (Cα), 53.6 
(C5,6), 37.3 (C1), 36.1 (C2), 33.5 (Cγ), 31.9 (C3), 30.2 (C4,7), 28.3 (Cβ). IR (KBr) ῡ 
3423, 3065, 2942, 1681, 1535, 1439, 1209, 1135, 801, 723 cm
-1
. HRMS (ESI
+
): m/z 
calcd for C31H38N3O5 [M+H]
+
 532.2806, found 532.2823. HPLC-MS: tR = 2.72 min 
(97%).  
 
4.3.7. General procedure for the synthesis of esters 
The corresponding acid L-(11-13) or D-11 (1 mmol) was dissolved in EtOH or n-
hexanol (20 mL) at 0 ºC and then, thionyl chloride (SOCl2, 1.2 mmol) was added 
dropwise. The reaction mixture was stirred for 16 h at room temperature and then the 
solvent was evaporated at reduced pressure. The crude was purified by flash column 
chromatography as indicated in each case. 
 
4.3.7.1. N-Benzoyl-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl (L-14) 
Following the general procedure, the reaction of acid L-11 (0.20 g, 0.44 mmol), 
EtOH (10 mL), and SOCl2 (39.0 μL, 0.53 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 98:2 to 90:10), afforded 
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compound L-14 as a white solid (0.13 g, 0.27 mmol, 61%) of mp 117-118 ºC and [α]D
20
: 
-8.1 (c = 1, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ 7.87 (m, 2H, H Ar), 7.80 (m, 1H, 
NHCα), 7.45 (m, 8H, H Ar), 6.78 (br s, 1H, NHCOCγ), 4.62 (m, 1H, Hα), 4.17 (q, J = 
7.2 Hz, 2H, H1’’), 3.95 (s, 2H, H8), 3.24 (m, 4H, H1, 5eq, 6eq), 2.49 (m, 2H, 5ax, 6ax), 
2.38 (m, 2H, Hγ), 2.24 (m, 1H, Hβ1), 2.13 (m, 1H, Hβ2), 1.77 (m, 4H, H2, 4eq, 7eq), 
1.48 (m, 3H, H3, 4ax, 7ax), 1.27 (t, J = 7.2 Hz, 3H, H2’’). 13C NMR (100 MHz, 
CDCl3): δ 172.8 (COCγ), 172.1 (COCα), 167.5 (CONHCα), 133.6 (C Ar), 132.0 (C Ar), 
131.2 (2C Ar), 129.7 (2C Ar), 129.2 (C Ar), 128.7 (4C Ar), 127.4 (C Ar), 61.7 (C1’’), 
61.3 (C8), 53.1 (Cα), 52.5 (C5,6), 36.8 (C1), 35.2 (C2), 32.8 (Cγ), 31.7 (C3), 29.2 
(C4,7), 27.8 (Cβ), 14.3 (C2’’).  IR (KBr) ῡ 3436, 3315, 3067, 3027, 2929, 2800, 1733, 
1646, 1548, 1453, 1342, 1301, 1177, 1028, 730, 697 cm
-1
. HRMS (ESI
+
): m/z calcd for 
C28H38N3O4 [M+H]
+
 480.2857, found 480.2837. HPLC-MS: tR = 2.71 min (100%).  
 
4.3.7.2. N-Benzoyl-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl (D-14) 
Following the general procedure, the reaction of acid D-11 (0.15 g, 0.33 mmol), 
EtOH (10 mL), and SOCl2 (29 μL, 0.40 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 97:3 to 90:10), afforded 
compound D-14 as a white solid (0.14 g, 0.29 mmol, 89%) of mp 90-92 ºC and [α]D
20
: 
+5.4 (c = 1, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ 7.86 (m, 2H, H Ar), 7.80 (m, 1H, 
NHCα), 7.44 (m, 8H, H Ar), 6.82 (br s, 1H, NHCOCγ), 4.60 (m, 1H, Hα), 4.17 (q, J = 
7.2 Hz, 2H, H1’’), 3.95 (s, 2H, H8), 3.23 (m, 4H, H1, 5eq, 6eq), 2.50 (m, 2H, 5ax, 6ax), 
2.37 (m, 2H, Hγ), 2.23 (m, 1H, Hβ1), 2.11 (m, 1H, Hβ2), 1.77 (m, 4H, H2, 4eq, 7eq), 
1.44 (m, 3H, H3, 4ax, 7ax), 1.25 (t, J = 7.2 Hz, 3H, H2’’). 13C NMR (100 MHz, 
CDCl3): δ 172.8 (COCγ), 172.1 (COCα), 167.5 (CONHCα), 133.5 (C Ar), 132.0 (C Ar), 
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131.3 (2C Ar), 129.8 (2C Ar), 129.2 (C Ar), 128.7 (4C Ar), 127.4 (C Ar), 61.7 (C1’’), 
61.1 (C8), 53.1 (Cα), 52.5 (C5,6), 36.8 (C1), 35.2 (C2), 32.8 (Cγ), 31.7 (C3), 29.0 
(C4,7), 27.8 (Cβ), 14.3 (C2’’). IR (KBr) ῡ 3430, 3062, 2931, 1737, 1651, 1537, 1455, 
1208, 1028, 701 cm
-1
. HRMS (ESI
+
): m/z calcd for C28H38N3O4 [M+H]
+
 480.2857, 
found 480.2875. HPLC-MS: tR = 2.62 min (100%).  
 
4.3.7.3. N-Benzoyl-D-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-n-hexyl (D-1) 
Following the general procedure, the reaction of acid D-11 (0.10 g, 0.22 mmol), n-
HexOH (4 mL), and SOCl2 (19.4 μL, 0.27 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 97:3 to 90:10), afforded 
compound D-1 as a white solid (0.10 g, 0.19 mmol, 86%) of mp 68-70 ºC and [α]D
20
: 
+10.2 (c = 1, CHCl3). 
1
H NMR (500 MHz, CDCl3): δ 7.87 (m, 2H, H Ar), 7.75 (m, 1H, 
NHCα), 7.45 (m, 8H, H Ar), 6.78 (br s, 1H, NHCOCγ), 4.64 (m, 1H, Hα), 4.12 (m, 2H, 
H1’’), 4.03 (s, 2H, H8), 3.24 (m, 4H, H1, 5eq, 6eq), 2.54 (m, 2H, H5ax, 6ax), 2.38 (m, 
2H, Hγ), 2.23 (m, 1H, Hβ1), 2.13 (m, 1H, Hβ2), 1.80 (m, 2H, H2, 4eq, 7eq), 1.62 (m, 
2H, H2’’), 1.46 (m, 3H, H3, 4ax, 7ax), 1.29 (m, 6H, H3’’, 4’’, 5’’), 0.86 (t, J = 7.3 Hz, 
3H, H6’’). 13C NMR (125 MHz, CDCl3): δ 172.9 (COCγ), 172.1 (COCα), 167.5 
(CONHCα), 133.5 (C Ar), 132.1 (C Ar), 131.4 (2C Ar), 130.1 (2C Ar), 129.3 (C Ar), 
128.7 (4C Ar), 127.4 (C Ar), 65.9 (C1’’), 61.1 (C8), 53.1 (Cα), 52.5 (C5,6), 36.7 (C1), 
35.2 (C2), 32.8 (Cγ), 31.5 (C3), 28.9 (C4,7), 28.6 (C2’’), 27.9 (Cβ), 25.6 (C3’’), 22.6 
(C4’’,5’’), 14.1 (C6’’). IR (KBr) ῡ 3430, 3065, 2931, 1738, 1647, 1535, 1455, 1202, 
749, 701 cm
-1
. HRMS (ESI
+
): m/z calcd for C32H46N3O4 [M+H]
+
 536.3483, found 
536.3478. HPLC-MS: tR = 3.38 min (95%). 
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4.3.7.4. N-[Indole-3-carbonyl]-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl (L-
15) 
Following the general procedure, the reaction of acid L-12 (0.10 g, 0.20 mmol), 
EtOH (5 mL), and SOCl2 (17.9 μL, 0.24 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 95:5 to 90:10), afforded 
compound L-15 as a yellow solid (0.053 g, 0.10 mmol, 50%) of mp 87-90 ºC and [α]D
20
: 
-9.1 (c = 1, CH3OH). 
1
H NMR (400 MHz, CD3OD): δ 8.11 (m, 1H, H Ar), 8.00 (s, 1H, 
H Ar), 7.40 (m, 6H, H Ar), 7.16 (m, 2H, H Ar), 4.57 (m, 1H, Hα), 4.20 (q, J = 7.2 Hz, 
2H, H1’’), 4.0 (m, 2H, H8), 3.16 (m, 4H, H1, 5eq, 6eq), 2.71 (m, 2H, 5ax, 6ax), 2.40 
(m, 2H, Hγ), 2.29 (m, 1H, Hβ1), 2.08 (m, 1H, Hβ2), 1.80 (m, 2H, H4eq, 7eq), 1.49 (m, 
1H, H3), 1.35 (m, 4H, H2, 4ax, 7ax), 1.27 (t, J = 7.2 Hz, 3H, H2’’). 13C NMR (100 
MHz, CD3OD): δ 174.8 (COCγ), 174.0 (COCα), 168.4 (CONHCα), 138.1 (2C Ar), 
132.1 (C Ar), 130.9 (C Ar), 130.2 (C Ar), 129.7 (2C Ar), 127.2 (C Ar), 123.7 (C Ar), 
122.2 (C Ar), 121.9 (C Ar), 113.0 (C Ar), 111.3 (C Ar), 62.4 (C1’’), 61.7 (Cα), 53.4 
(C5,6), 37.2 (C1), 36.0 (C2), 33.3 (Cγ), 31.9 (C3), 30.2 (C4,7), 28.0 (Cβ), 14.5 (C2’’). 
IR (KBr) ῡ 3401, 3264, 3088, 2930, 1735, 1632, 1538, 1455, 1199, 1029, 750, 701 cm-1. 
HRMS (ESI
+
): m/z calcd for C30H39N4O4 [M+H]
+
 519.2966, found 519.2987. HPLC-
MS: tR = 2.72 min (96%).  
 
4.3.7.5. N-[Indole-3-carbonyl]-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-n-hexyl 
(L-16) 
Following the general procedure, the reaction of acid L-12 (0.11 g, 0.22 mmol), n-
HexOH (4 mL), and SOCl2 (19.6 μL, 0.27 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 98:2 to 90:10), afforded 
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compound L-16 as a yellow solid (0.086 g, 0.15 mmol, 70%) of mp 85-87 ºC and [α]D
20
: 
-8.0 (c = 1, CH3OH). 
1
H NMR (500 MHz, CD3OD): δ 8.01 (m, 1H, H Ar), 7.92 (s, 1H, 
H Ar), 7.32 (m, 6H, H Ar), 7.07 (m, 2H, H Ar), 4.49 (m, 1H, Hα), 4.05 (m, 2H, H1’’), 
3.94 (m, 2H, H8), 3.08 (m, 4H, H1, 5eq, 6eq), 2.62 (m, 2H, 5ax, 6ax), 2.32 (m, 2H, Hγ), 
2.21 (m, 1H, Hβ1), 2.01 (m, 1H, Hβ2), 1.70 (m, 2H, H4eq, 7eq), 1.54 (m, 2H, H2’’), 
1.40 (m, 1H, H3), 1.21 (m, 10H, H2, 4ax, 7ax, 3’’, 4’’, 5’’), 0.73 (t, J = 7.2 Hz, 3H, 
H6’’). 13C NMR (125 MHz, CD3OD): δ 174.7 (COCγ), 174.1 (COCα), 168.4 
(CONHCα), 138.1 (2C Ar), 132.1 (2C Ar), 130.9 (C Ar), 130.2 (C Ar), 129.6 (2C Ar), 
127.3 (C Ar), 123.7 (C Ar), 122.2 (C Ar), 121.9 (C Ar), 113.0 (C Ar), 111.4 (C Ar), 
66.4 (C1’’), 61.7 (C8), 53.6 (C5,6), 53.4 (Cα), 37.3 (C1), 35.9 (C2), 33.4 (Cγ), 32.6 
(C3’’), 31.9 (C3), 30.1 (C4,7), 29.7 (C2’’), 27.9 (Cβ), 26.7 (C4’’), 23.6 (C5’’), 14.3 
(C6’’). IR (KBr) ῡ 3412, 3266, 3086, 2930, 1737, 1635, 1538, 1455, 1196, 1135, 750, 
701 cm
-1
. HRMS (ESI
+
): m/z calcd for C34H47N4O4 [M+H]
+
 575.3592, found m/z 
575.3585. HPLC-MS: tR = 3.28 min (95%). 
 
4.3.7.6. N-[6-Methoxy-2-naphthoyl]-L-Glu[NH-2-(1-benzylpiperidin-4-yl)ethyl]-O-ethyl 
(L-17) 
Following the general procedure, the reaction of acid L-13 (0.082 g, 0.15 mmol), 
EtOH (5 mL), and SOCl2 (13.1 μL, 0.18 mmol), followed by flash column 
chromatography using CH2Cl2/MeOH (increasing polarity from 95:5 to 90:10), afforded 
compound L-17 as a white solid (0.063 g, 0.11 mmol, 75%) of mp 68-71 ºC and [α]D
20
: 
-8.3 (c = 1, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ 8.34 (m, 1H, H Ar), 7.80 (m, 4H, 
3H Ar, NHCα), 7.47 (m, 2H, H Ar), 7.35 (m, 3H, H Ar), 7.13 (m, 2H, H Ar), 6.85 (m, 
1H, NHCOCγ), 4.66 (m, 1H, Hα), 4.19 (q, J = 7.2 Hz, 2H, H1’’), 3.91 (s, 5H, H11’’, 
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H8), 3.21 (m, 4H, H1, 5eq, 6eq), 2.40 (m, 4H, Hγ, 5ax, 6ax), 2.26 (m, 1H, Hβ1), 2.15 
(m, 1H, Hβ2), 1.75 (m, 4H, H2, 4eq, 7eq), 1.40 (m, 3H, H3, 4ax, 7ax), 1.26 (t, J = 7.2 
Hz, 3H, H2’’). 13C NMR (100 MHz, CDCl3): δ 172.9 (COC-γ), 172.2 (COC-α), 167.6 
(CONHC-α), 159.4 (C6’), 136.6 (2C Ar), 131.4 (C Ar), 130.7 (C Ar), 130.0 (C Ar), 
129.3 (3C Ar), 128.5 (C Ar), 128.1 (C Ar), 128.0 (C Ar), 127.3 (C Ar), 124.4 (C Ar), 
120.0 (C Ar), 105.8 (C Ar), 61.8 (C1’’), 61.0 (C8), 55.6 (C11’’), 53.1 (Cα), 52.5 (C5,6), 
36.8 (C1), 35.2 (C2), 33.0 (Cγ), 31.6 (C3), 28.9 (C4,7), 27.9 (Cβ), 14.4 (C2’’). IR (KBr) 
ῡ 3413, 3060, 2933, 1737, 1644, 1630, 1535, 1502, 1456, 1267, 1214, 1028, 860, 749, 
701 cm
-1
. HRMS (ESI
+
): m/z calcd for C33H42N3O5 [M+H]
+
 560.3119, found 560.3121. 
HPLC-MS: tR = 2.97 min (99%). 
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4.4. Biochemical studies 
4.4.1. Inhibition of human AChE and BuChE 
The method of Ellman et al. was followed [39]. The assay solution consisted of 0.1 
M phosphate buffer pH 8, 400 M 5,5´-dithiobis(2-nitrobenzoic acid) (DTNB, Ellman’s 
reagent), 0.05 U/mL hAChE (human recombinant acetylcholinesterase, Sigma Chemical 
Co.) or 0.024 U/mL hBuChE (butyrylcholinesterase from human serum, Sigma 
Chemical Co.), and 800 M acetylthiocholine iodide, or 500 M butyrylthiocholine as 
the substrate of the enzymatic reaction, respectively. Compounds were added to the 
assay solution and pre-incubated with the enzyme for 5 minutes at 30 ºC. After that 
period, the substrate was added. The absorbance changes at 412 nm were recorded for 5 
minutes with a UV/Vis microplate spectrophotometer, Multiskan Spectrum, Thermo-
Electron Co. The reaction rates were compared and the percent inhibition due to the 
presence of tested compound was calculated. The IC50 is defined as the concentration of 
each compound that reduces at 50% the enzymatic activity without any inhibitor, which 
is expressed as the mean ± SEM of three independent experiments. 
 
4.4.2. Neuroprotection Studies 
4.4.2.1. Culture of SH-SY5Y cells 
SH-SY5Y cells were maintained in a 1:1 mixture of F-12 Nutrient Mixture (Ham12) 
(Sigma-Aldrich) and Eagle’s minimum essential medium (EMEM) supplemented with 
15 non-essential amino acids, 1 mM sodium pyruvate, 10% heat-inactivated foetal 
bovine serum (FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin (reagents 
from Invitrogen). Cultures were seeded into flasks containing supplemented medium 
 40 
and maintained at 37 °C in a humidified atmosphere of 5% CO2 and 95% air (v/v). For 
assays, SH-SY5Y cells were sub-cultured in 48-well plates at a seeding density of 1 x 
10
5
 cells per well. Cells were treated with the drugs before confluence in F-12/EMEM 
with 1% FBS. All the cells used in this study were used passages below 18. 
4.4.2.2. Rotenone/oligomycin-A toxicity 
Concentrated solutions of drugs were prepared in DMSO. For the control group, 
0.1% DMSO was incubated having the same DMSO concentration of the tested 
compound’s group. Compounds, at the concentration of 0.3 μM, were administered 24 h 
before adding the cytotoxic stimuli (rotenone/oligomycin A); then, cells were co-
incubated for another 24 h with the drug in the presence of stimuli. All toxic stimuli 
were incubated in serum-free medium. 
4.4.2.3. In vitro OGD/R model of ischemia 
Briefly, after 24 h of pre-treatment with compounds of interest, the culture medium 
was changed to the glucose-free PBS 0.1 M with 2-deoxyglucose containing either 
melatonin (0.1 μM, positive control) or target compounds at 0.3 μM before placing 
them into an anaerobic chamber that was flushed with 5% CO2 and 95% N2 (v/v). The 
same anaerobic gas mixture was bubbled previously through the glucose-free PBS with 
2-deoxyglucose. The cell cultures within the anaerobic chamber were kept in a 
humidified incubator at 37 ºC for 4 h. To terminate the OGD, the PBS medium was 
changed to normal medium containing the same concentrations of tested compound 
alone before returning to the normoxic incubating conditions. In the sham-OGD groups, 
the cell cultures were subjected to the same experimental procedures plus vehicle 
without exposure to OGD. 
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4.4.2.4. Quantification of Viability by MTT in SH-SY5Y cells 
Cell viability, virtually the mitochondrial activity of living cells, was measured by 
quantitative colorimetric assay with MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-
tetrazolium bromide, Sigma-Aldrich), as described previously [53]. To evaluate 
viability after the treatment with the compounds, MTT was added to all wells (5 
mg/mL) and allowed to incubate in the dark at 37 °C for 2 h. The tetrazolium ring of 
MTT is cleaved by active reductases producing a precipitated formazan derivative. The 
formazan produced was dissolved by adding 300 μL DMSO, resulting in a coloured 
compound whose optical density was measured in an ELISA reader at 540 nm in 100 
μL of the resulting solution for each well transferred to a 96-well plate. All MTT assays 
were performed in triplicate. 
 
4.4.3. In vitro blood–brain barrier permeation assay 
Prediction of the brain penetration was evaluated using a parallel artificial membrane 
permeation assay (PAMPA), in a similar manner as described previously [47]. 
Commercial drugs, phosphate buffer saline solution at pH 7.4 (PBS), and dodecane 
were purchased from Sigma-Aldrich, Across and Fluka. Millex filter units (PVDF 
membrane, diameter 25 mm, pore size 0.45 m) were acquired from Millipore. The 
porcine brain lipid (PBL) was obtained from Avanti Polar Lipids. The donor microplate 
was a 96-well filter plate (PVDF membrane, pore size 0.45 m) and the acceptor 
microplate was an indented 96-well plate, both from Millipore. The acceptor 96-well 
microplate was filled with 180 L of PBS:ethanol (70:30) and the filter surface of the 
donor microplate was impregnated with 4 L of porcine brain lipid (PBL) in dodecane 
(20 mg mL-1). Compounds were dissolved in PBS:ethanol (70:30) at 1 mg mL-1, filtered 
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through a Millex filter, and then added to the donor wells (180 L). The donor filter 
plate was carefully put on the acceptor plate to form a sandwich, which was left 
undisturbed for 4 h at 25 ºC. After incubation, the donor plate is carefully removed and 
the concentration of compounds in the acceptor wells was determined by UV 
spectroscopy. Every sample was analysed at five wavelengths, in four wells and in three 
independent runs, and the results are given as the mean ± standard deviation. In each 
experiment, 15 quality control standards of known BBB permeability were included to 
validate the analysis set. 
 
4.4.4. Measurement of cytosolic Ca
2+
 transients in SH-SY5Y neuroblastoma cells 
SH-SY5Y cells were plated in black, bottom transparent 96-well plates and grown at 
confluence. Cells were loaded with 4 M Fluo-4/AM for 45 min at 37 °C in MEM. 
Then, cells were washed twice with Krebs-HEPES solution containing the following 
composition (in mM): 140 NaCl, 5.6 KCl, 1.2 MgCl2, 2 CaCl2, 10 HEPES, 11 D-
glucose, at pH 7.4 and kept at room temperature for 15 min before the beginning of the 
experiment. Compounds were incubated 15 min before injecting potassium (70 mM) to 
enhance VDCC opening and [Ca
2+
]c increase. Fluorescence measurements were carried 
out for 14 seconds after the injection of the agonists in a microplate reader (FLUOstar 
Optima, BMG, Germany). Wavelengths of excitation and emission were 485 and 520 
nm, respectively. At the end of the experiment, 50 μL of triton 5% was added to each 
well to calculate maximum fluorescence (Fmax) and then 50 μL of MnCl2 1 M to obtain 
the minimum fluorescence (Fmin). Drug-evoked responses were expressed as percentage 
of the fluorescence values at each time point (F) minus minimum fluorescence values 
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(F0) divided by Fmax-Fmin as: F520=(F-F0) / (Fmax-Fmin)%  The maximum value of F520, 
obtained for each experiment, was considered as the Peak F520 value. 
 
4.4.5. Preparation of rat hippocampal slices and induction of oxygen and glucose 
deprivation followed by re-oxygenation (OGD/R) 
All experiments were performed using adult male Sprague-Dawley rats (275-325 g) 
from a colony of our animal quarters. The experiments were performed after approval of 
the protocol by the UAM Institutional Ethics Committee. All efforts were made to 
minimize animal suffering and to reduce the number of animals used in the 
experiments. 
Following a described protocol [49], rats were quickly decapitated under sodium 
pentobarbital anesthesia (60 mg/kg, i.p.), forebrains were removed from the skull and 
placed into ice-cold Krebs bicarbonate dissection buffer (pH 7.4), containing (in mM): 
NaCl 120, KCl 2, CaCl2 0.5, NaHCO3 26, MgSO4 10, KH2PO4 1.18, glucose 11 and 
sucrose 200. The chamber solutions were pre-bubbled with either 95% O2/5% CO2 or 
95% N2/5% CO2 gas mixtures, for at least 45 min before slice immersion, to ensure O2 
saturation or removal. The hippocampi were quickly dissected, and slices (350 µm 
thick) were rapidly prepared using a McIlwain Tissue Chopper. Then, the slices were 
transferred to vials of sucrose-free dissection buffer, bubbled with 95% O2/5% CO2 in a 
water bath at room temperature for 60 min to recover from slicing trauma before 
starting the experiments (equilibration period). The slices corresponding to the control 
group were incubated 15 min in a Krebs solution with the following composition (in 
mM): NaCl 120, KCl 2, CaCl2 2, NaHCO3 26, MgSO4 1.19, KH2PO4 1.18 and glucose 
11; this solution was equilibrated with 95% O2/5% CO2. Oxygen and glucose 
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deprivation was induced by incubating the slices for a 15 min period in a glucose-free 
Krebs solution, equilibrated with a 95% N2/5% CO2 gas mixture; glucose was replaced 
by 2-deoxyglucose. After this OGD period, the slices were returned back to an 
oxygenated normal Krebs solution containing glucose (re-oxygenation period). 
Experiments were performed at 37 ºC. A control and OGD group were included in all 
experiments and four drug concentrations were tested in each experiment. When treated, 
OGD slices received compound L-3 and remained there during the OGD and re-
oxygenation period. 
Hippocampal cell viability was determined through the ability of the cells to reduce 
MTT [53]. Hippocampal slices were collected immediately after the re-oxygenation 
period and were incubated with MTT (0.5 mg/mL) in Krebs bicarbonate solution for 30 
min at 37 ºC. The tetrazolium ring of MTT is cleaved by active dehydrogenases to 
produce a precipitated formazan derivative. The formazan produced was solubilized by 
adding 200 µL DMSO, resulting in a coloured compound whose optical density was 
measured in an ELISA reader at 540 nm. 
Data are represented as means ± standard error of the mean. Comparisons between 
experimental and control groups were performed by One-way ANOVA followed by 
Newman-Keuls post-hoc test. Differences were considered to be statistically significant 
when p < 0.05. All statistical procedures were carried out using GraphPad Prism 
software version. 
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List of captions 
 
Figure 1. Structures of donepezil, IQM-9.21 (L-1), and new L- and D-Glu derivatives 
 
Figure 2. Inhibition by compounds L-1 and L-3 of the increment of [Ca2+]c evoked by 
K+ stimulation of neuronal SH-SY5Y cells. Panels A and B show the % of [Ca2+]c 
increase without any compound (basal) and in presence of increasing concentrations of 
L-1 and L-3 respectively. Nifedipine (10 µM) was used as positive control. Panel C 
shows concentration-response curves, measured as the maximum amplitude from 
baseline to the top of the plateau, fitted to non-linear curves for L-1 (square, continuous 
line) and L-3 (triangle, dotted line) and calculated IC50 values. 
 
Figure 3. Compound L-3 increases cell viability of rat hippocampal slices subjected to 
OGD/R. The experimental protocol is illustrated on the top part of the figure. The graph 
corresponds to the mean ± SEM of 4 independent experiments in triplicate. 
###
p<0.001 
respect control slices (not exposed to OGD/R) and *p<0.05, **p<0.01, ***p<0.001 
respect to slices subjected to OGD/R. Data of compound L-1 are taken from Ref. [36] 
 
Scheme 1. Solid-phase synthesis of L- and D-Glu derivatives with an N-
benzylpiperidine in the γ-position 
 
Table 1. Summary results of the lipase-catalysed preparative reactions 
 
Table 2. Inhibitory activities of new compounds in hAChE and hBuChE [IC50 (µM)]; 
neuroprotection (%) elicited by compounds at 0.3 M in the human neuroblastoma cell 
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line SH-SY5Y, subjected to (i) the combination of rotenone (30 M) and oligomycin A 
(10 M) (R/O) or (ii) the oxygen-glucose deprivation followed by re-oxygenation 
(OGD/R); permeability values of compounds in the PAMPA-BBB assay (Pe, 10
-6
 cm s
-
1
) with their predictive penetration in the CNS
a
 
